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ANTITUMOR ACTIVITY OF RECOMBINANT
INTERLEUKIN 6 IN MICE
BY J. J. MULE, J. K. McINTOSH, D. M. JABLONS, AND S. A. ROSENBERG
From the Surgery Branch, Division of Cancer Treatment, National Cancer Institute,
National Institutes of Health, Bethesda, Maryland 20892
IL-6 has been recently cloned and expressed by recombinant DNA techniques
in Escherichia coli (1-3) . It is a 19-30-kD phosphoglycoprotein that can elicit a broad
range of immune and acute phase responses. IL-6 can act as a cytotoxicT cell differen-
tiation factor as well as astimulatory factor forT cells and B cells (4-6). Stimulation
ofhepatocytes by IL-6 results in the synthesis of major acute-phase proteins associated
with inflammation (7). We (8) and others (9) have shown that the systemic adminis-
tration of human rTNF-ci to patients with advanced cancer induced circulating, bio-
logically active IL-6 . In addition, IL-2 administration could induce circulating TNF
and IL-6 in treated patients (8). In mice, tumor bearers consistently produced more
IL-6 in response to rTNF than did nontumor bearers. Moreover,low levels ofendog-
enous circulating IL-6 could be detected as aconsequence ofthe tumor-bearing state,
since the sera of mice not receiving recombinant cytokines contained levels of IL-6
that paralleled the extent of tumor burden (10) . Based on these studies, it became
apparent that IL-6 may be an important cytokine in the host's immune and meta-
bolic responses to cancer. The availability of human rIL-6 prompted us to under-
take in vivo studies to examine the therapeutic efficacy of this cytokine in models
of established tumors in mice.
Materials and Methods
Mice.
	
Female C57BL/6 mice, 12-16 wk old, were obtained from TheJackson Laboratory
(Bar Harbor, ME) and from the Small Animal Section, Veterinary Resources Branch, Na-
tional Cancer Institute .
Recombinant Cytokines. Human rIL-2 was kindly supplied by the Cetus Corp. (Emeryville,
CA) and had a specific activity of 3 x 106 U/mg. The biologic and biochemical activities
of rIL-2 have been described elsewhere (11, 12) .
Human rIL-6 (Genetics Institute, Cambridge, MA) was purified to homogeneity from
E. coli supernatants and had an approximate activity of 1-4 x 106 U/mg, as determined by
the plasmacytoma proliferation assay (13, 14) ; the protein concentration ofthe stock material
was 276-300 Rg/ml of buffer (50 mM sodium acetate, 200 mM sodium chloride pH 5-5.5)
with an endotoxin level of 2-4 EU/ml .
Human rTNFcx (Cetus Corp .) had a specific activity of 2.2 x 10' U/mg as determined
by the L929 cytolytic bioassay (15) .
B9 Bioassay. Serum rIL-6 levels were detected by a [ 3H]TdR uptake assay using the IL-
6-dependent murine hybridoma subclone B9 as described previously (13, 14) . The specificity
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ofproliferation ofthe B9 hybridoma cells to IL-6 and not to a variety of other known cytokines
has been reported elsewhere (8, 10) . Known preparations of HL-6 were diluted in heat-
inactivated FCS and tested concurrently as a standard . SD ofreplicate samples were within 10%.
Tumors. The syngeneic sarcomas (MCA-105, -106, and -203) were induced in our labora-
tory by 0.1 ml of logo 3-methylcholanthrene (MCA) in sesame oil injected intramuscularly
into C57BL/6 mice (16). The syngeneic colon adenocarcinoma, MC-38, was induced by
dimethylhydrazine. Single cell suspensions were prepared for injection by excising growing,
fresh tumor transplanted subcutaneously in syngeneic mice (second to ninth passage in vivo),
mincing the tissue in HBSS (Biofluids, Rockville, MD), and stirring it in a triple-enzyme
mixture (5 ml deoxyribonuclease type IV [0.01-0.02 mg/ml], 5 ml collagenase type IV [1
mg/ml], and 5 ml hyaluronidase type V [0.1 mg/ml ; Sigma Chemical Co., St . Louis, MO]
in HBSS [35 ml]) for 3 h at room temperature (17) . The dispersed tumor cells were collected,
passed through 100-guage nylon mesh (Nitex ; Lawshe, Rockville, MD), and washed three
times in HBSS . The cells were then adjusted to the appropriate cell concentration for injec-
tion into mice .
Tumor Therapy Models. C57BL/6 mice were injected intravenously (to generate pulmo-
nary metastases) or intrasplenically (to generate hepatic metastases) with tumor cells sus-
pended in HBSS (5-8 x 10 5 cells/ml) as described previously (17, 18). In some experiments,
mice were irradiated by exposure to a cesium-137 source for 4.8 min, which yielded a total
body radiation dose of 500 rad . The irradiation was performed 6 h before the injection of
tumor cells. Starting on day 3 after tumor induction, mice were given intraperitoneal injec-
tions (1 ml thrice daily) ofeither HBSS, rIL-6, or rIL-2 for 4 to 6 consecutive days . Between
days 12 and 19 after tumor induction, the mice were ear tagged, randomized, and killed for
enumeration of metastatic lung or liver nodules as described (17, 18) . Complete enumeration
(blind fashion) of metastases was possible because of the distinct white nodules formed on
the blackened surface ofthe lungs or liver (intratracheal injection [for lungs] or intravenous
injection via the lateral tail vein [for liver] with a 15 percent solution of India Ink) when
bleached by Fekette's solution (17, 18) . Lungs or livers with confluent metastases (or too
numerous to count) were assigned an arbitrary value of 250 because in these instances we
were able to count reliably only numbers ofmetastases approaching 250 (with the exception
of the MCA-106 sarcoma in which we could count distinct pulmonary metastases approaching
400) . Statistical analyses were performed by the Wilcoxon rank sum test . Two-sided p values
are presented in all experiments .
In other experiments, C57BL/6 mice were injected subcutaneously with 5 x 105 MCA-
106 sarcoma cells suspended in 0.05 ml HBSS as described previously (19) . 10 d later, when
the tumors had achieved a size of 6-7 mm in diameter, the mice each received a single intra-
venous injection of 1 ml excipient or rTNF in HBSS containing 0.1% pooled heat-inactivated
normal C57BL/6 mouse serum . These mice were then further subdivided into two groups,
and received intraperitoneal injections of either 0.5 ml HBSS alone or rIL-6 in HBSS twice
a day for 5 consecutive days . Mice were then ear tagged, randomized, and followed for tumor
progression/regression and for survival. Statistical significance was determined by 7C z anal-
ysis ; two-sided p values are presented .
Results and Discussion
Using the B9 hybridoma cell bioassay (13, 14), we determined that the serum half-
life of IL-6 in C57BL/6 mice was -7 min after an intravenous injection of 1 Ag,
with 240 hybridoma growth factor (HGF) units detected at 1 h, and disappearance
by 2 h (Fig . 1) . By the intraperitoneal route, sustained levels of biologically active
IL-6 could be detected out to 6 h (240 HGF units) following the administration of
10 p,g, with a serum half-life of N3 h (Fig . 1) . Because prolonged, circulating levels
of IL-6 could be achieved in sera after an intraperitoneal injection, we examined
the effect ofHL-6 on growing syngeneic murine tumors using this route of adminis-
tration .
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FIGURE 1 . Serum half-life of
rIL-6 in mice. Normal C57BL/6
mice received a single i .v. or i .p.
injection of 1 p.g or 10 wg rIL-6,
respectively, diluted in 0 .5 ml
HBSS. Mice were then bled at
specified time points after injec-
tion ; the sera from two mice per
time point were pooled. IL-6 1ev-
els were determinedas described
in Materials and Methods .
We (12) and others (20) have shown that the systemic administration of high-dose
rIL-2 alone could mediate the regression of a variety of murine tumors established
at subcutaneous as well as visceral sites. To examine whether or not rIL-6 could
also mediate antitumor effects when used alone at high doses, we directly compared
the administration of this cytokine in amounts comparable to known therapeutic
doses of rIL-2. C57BL/6 mice were injected intravenously with MCA-105, -106, or
-203 sarcomaor MC-38 colon adenocarcinoma cells or intrasplenically with MCA-
203 sarcoma cells to induce pulmonaryandhepatic metastases, respectively. On day
3 after tumor injection, when multiple foci ofmicrometastases were established (as
assessed by histologic examination of lungs or liver), these mice then received in-
traperitoneal injections of rIL-6, rIL-2, or HBSS for 4-6 consecutive days . We as-
sayed the effect of these treatments on metastasis development between days 12 and
19 . The results of eight separate experiments (Table I) showed that metastases from
all four tumors were significantly reduced by the administration of rIL-6 alone. As
reported in earlier studies (12), rIL-2 alone at high dose also resulted in marked
tumor regression, with the exception ofthe MC-38 adenocarcinoma. In several ex-
periments the injections of rIL-2 (33.3 or 50.0 ug per injection) were stopped after
12 or 13 doses because mice were showing visible signs of toxicity ; manifested as
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TABLE I
Comparison between the Antitumor Efficacy of the Systemic Administration of rIL-6
and rIL-2 Against Established Pulmonary or Hepatic Metastases from
Four Distinct, Weakly Immunogenic Syngeneic Tumors
* Number in parentheses ; total number of cytokine injections administered .
: p < 0.01 compared with the group receiving no treatment (HBSS) .
tachypnea, edema, lethargy, and piloerection (21) . In contrast, mice treated with
rIL-6 at similar doses did not show outward signs oftoxicity. Moreover, the adminis-
tration of high dose rIL-6 did not cause substantial increases in wet weights of the
lungs compared . with HBSS control mice (data not shown) ; thus, unlike rIL-2, rIL-6
did not appear to elicit the vascular leak syndrome (21) . In three combined experi-
ments (E, F, G), when rIL-2 wascontinued for a full 6-d course of 18 total injections
Exp. Tumor Site
Treatment
Wg rIL-2 hg rIL-6
(per injection)
Number of
treatment-
related deaths/
total treated
Mean
number of
metastases
A MCA-203 Lungs - - 0/6 205
33 .3 (13)* - 0/6 181
- 33 .3 (15) 0/6 231
B MCA-203 Lungs - - 0/12 >250
33 .3 (12) - 0/6 671
- 33 .3 (15) 0/6 461
C MCA-106 Lungs - - 0/12 385
33 .3 (12) - 1/6 137 :
- 33 .3 (15) 0/6 158:
D MCA-203 Liver - - 0/6 >250
33 .3 (15) - 0/6 lit
- 6 .6 (15) 0/5 101
- 33 .3 (15) 0/6 11 :
E MC-38 Lungs - - 0/12 207
10 .0 (18) - 0/6 237
50 .0 (12) - 1/6 221
50 .0 (18) - 4/6 >250
- 10 .0 (18) 0/6 981
- 50 .0 (18) 0/6 21
F MCA-105 Lungs - - 0/10 225
10 .0 (18) - 0/6 631
50 .0 (12) - 2/6 141
50 .0 (18) - 3/6 251
- 10 .0 (18) 0/5 191
- 50 .0 (18) 0/6 5t
G MCA-105 Lungs - - 0/12 >250
50 .0 (18) - 7/12 2
- 50 .0 (18) 0/6 27t
H MC-38 Lungs - - 0/12 >230
10 .0 (15) - 0/6 243
50 .0 (12) - 0/6 >250
- 10 .0 (15) 0/6 41
- 50 .0 (15) 0/6 01
(50.0 IAg per injection), 14 of 24 mice died from treatment compared with 0 of 18
mice receiving rIL-6 (p2 < 0.005). Thus, rIL-6 at relatively high doses could mediate
the regression of established, 3-d metastases from four distinct syngeneic tumors
located in liver or lungs without apparent toxicity.
As an approach to study the mechanism ofthe rIL-6 effect we examined this treat-
ment simultaneously in normal and in immunosuppressed mice. Either normal
C57BL/6 mice or those that had received 500 rad of total body irradiation were in-
jected intravenously with MCA-203 sarcoma cells and then treated beginning on
day 3 with rIL-6 alone; comparisons were made with rIL-2 at comparable doses.
As shown in Fig. 2, host immunosuppression by irradiation eliminated the rIL-6-
(and rIL-2, as reported elsewhere [12]) mediated tumor regression in the lungs. A
similar findingwasobtained in two additional experiments, using the MCA-105 and
-106 sarcomas (not shown) . Therefore, the marked reduction of established micro-
metastatic disease mediated by rIL-6 was not a direct effect on the tumor per se,
but rather was through a relatively radiosensitive host component .
Since rTNF injections in tumor bearing mice were accompanied by the produc-
tion of detectable, albeit short-term, levels of circulating IL-6 (10), we next studied
what effect, if any, prolonged administration of relatively low doses of rIL-6 (5 fog
per injection) mighthave on the antitumor therapeutic efficacy ofrTNF in vivo. The
doses of rTNF chosen were based on our earlier in vivo studies of the synergistic
antitumor effects obtained when this cytokine was combined with rIL-2 (19) . The
long term survival of C57BL/6 mice bearing a subcutaneous, 10-d weakly immuno-
genic MCA-106 sarcoma after combination cytokine immunotherapy is shown in
the representative experiment of Fig. 3 (graph), in which repetitive injections of rIL-6
substantially augmented the small prolongation in survival achieved with 2 or 5 Wg
of rTNF alone. The combined cure rates of three separate experiments are shown
in the inset of Fig. 3. Treatment of the tumor-bearing mice with the combination
of a subtherapeutic dose of rTNF plus rIL-6 resulted in eradication of the tumor
in a significant proportion of animals, which was not observed with treatment by
either cytokine alone.
xoo
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FtcuRta 2. Effect of prior host im-
munosuppression by sublethal, total
.~ body irradiation on the antitumoreffect of rIL-6 in C57BL/6 mice
bearing 3-d MCA-203 pulmonary
"~ metastases . The nonirradiated arm of
this experiment is presented as experi-
ment B in Table I . Mice were injected
" i.p. with either HBSS, rIL-2 (33.3
hg/injection), or rIL-6 (33.3 leg/injec-
" tion), thrice daily for 4 (rIL-2) or 5
(HBSS, rIL-6) consecutive days, begin-
yen ning 3 d after tumor injection. The
number ofpulmonary metastases was
counted on day 13 . Each dot in the
" figure represents the number of king
Hess Hess .a-z n~-z n~.s ,,~.s nodules from an individual animal,
500 RAD 500 RAD 500 RAD with the meanvalue foreach treatment
group given in parentheses .
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10 20 30 4o 5o so 7o so 9o 11o
Days AfterTumor Injection
FIGURE 3 . Therapeutic effi-
cacy of the combination of rIL-6
and TNF. Treatment with
rTNF (2 or 5 jug) alone, rIL-6
(5 Frg perinjection) alone, or the
two cytokines combined was ini-
tiated 10 d after the s.c. injec-
tion of MCA-106 sarcoma cells
as described in Materials and
Methods. Mice without detect-
able tumor at 110 d had been
rendered completely free of
tumor for at least 80d. The data
in this figure are representative
of three individual studies, with
the combined cure rates from all
experiments presented inthe in-
sert. `, p = 0.05; ' `, (7 = 0.001 ;
compared with group receiving
no treatment.
Collectively, these data show that the systemic administration of rIL-6 alone at
high dose or at lower doses in combination with rTNF can mediate the regression
of murine syngeneic tumors in vivo. The mechanism(s) by which this antitumor
effect occurs does not appear to be through a direct action of rIL-6 on the tumor,
since host immunosuppression eliminates successful therapy. This latter finding differs,
therefore, from that reported by others in which IL-6 had a direct inhibitory (22)
or stimulatory (23) effect on the growth of certain tumor cells in vitro. It is conceiv-
able that secondary cytokinesmay be released or that cellular immune mechanisms
may be activated following rIL-6 administration that directly or indirectly result
in antitumor effects. Moreover, since IL-6 canhave avariety of growth anddifferen-
tiation effects on T cells, B cells, hepatocytes, and hematopoietic stem cells, the cel-
lular mechanism(s) operational in vivo during rIL-6-mediated tumor regression may
involve a complex interaction of several cell types. Preliminary histologic analysis
of the lungs ofmice receiving high dose rIL-6 has revealed infiltration with morpho-
logically activated lymphoid cells during the regression of pulmonary metastases
(not shown). The mechanism(s) ofIL-6 action in vivo as well as whether rIL-6 alone,
or in combination with other recombinant cytokines, will impact on more advanced
metastatic disease remain to be examined .
Summary
IL-6 possesses multiple biologic activities that affect a broad range ofcells including
those directly involved in immune responses as well as cells important in the sys-
temic response to infection or trauma . We now show that purified human rIL-6,
when administered alone at relatively high doses that are comparable to therapeutic
levels of IL-2, mediated substantial reductions in the number of pulmonary and
hepatic micrometastases from four distinct syngeneic tumors. Unlike IL-2, IL-6 in-
jections resulted in neither observable toxicity nor death of the treated mice at the
dose regimens used . Host immunosuppression by sublethal total-body irradiation
before the initiation of therapy prevented the IL-6 antitumor effect, thus suggesting
that IL-6 acted through a radiosensitive host component rather than directly on the
4 o--o I-
7 ~rum« Fml/rebl (x)
0 Hess W18(a)
g
3 'R6 0118 (a)
n rTNF (2 w1 0114(0)
E I I rTNF (2 Vg) +,. Gill (33)'
Z firs Is Fl) 2*4 (6)2 ~ fTNF l5 *a)+nee 11814 (74)°
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tumor itself. Moreover, the systemic administration of relatively low doses of IL-6
in combination with subtherapeutic doses of TNF to mice bearing an established
weakly immunogenic, syngeneic tumor at a subcutaneous site resulted in marked
tumor regression and cure rates . These studies represent the first demonstration of
tumor regression mediated by recombinant IL-6 in vivo.
We thank Dr. Gordon Wong andJoan Lanigan of Genetics Institute for helpful discussions
and for supplying human rIL-6; Drs . Mike Lotze and Rick Nordan for helpful suggestions;
and Dr. Jeff Weber for critical review of the manuscript .
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